8-K: Recursion Pharma Announces CEO Transition, Q3 Results & Key Milestones

Recursion Pharmaceuticals announced a leadership transition with Najat Khan appointed CEO, alongside reporting Q3 2025 financial results and significant partnership milestones, including a $30 million payment from Roche and Genentech.

Summary

• Najat Khan, Ph.D., currently Chief Research and Development Officer and Chief Commercial Officer, has been appointed Chief Executive Officer and President, effective January 1, 2026.
• Co-Founder Christopher Gibson, Ph.D., the current Chief Executive Officer and President, will transition to Chair of the Board and an interim Executive Advisor, effective January 1, 2026.
• Robert Hershberg, M.D., Ph.D., the current Chairman, will transition to Vice Chair and Lead Independent Director, effective January 1, 2026.
• Achieved a $30 million milestone payment from Roche and Genentech for delivering a second whole-genome map of microglial immune cells, bringing total upfront and milestone payments across all partnerships to over $500 million.
• Cash, cash equivalents, and restricted cash were $667.1 million as of September 30, 2025, and approximately $785 million (unaudited) as of October 9, 2025, providing a cash runway through the end of 2027 without additional financing.
• Total revenue for the third quarter of 2025 was $5.2 million, a decrease from $26.1 million in the third quarter of 2024.
• Net loss for the third quarter of 2025 was $162.3 million, compared to a net loss of $95.8 million for the third quarter of 2024.
• Research and development expenses increased to $121.1 million in Q3 2025 from $74.6 million in Q3 2024, primarily due to acquired IPR&D purchases and the business combination with Exscientia.
• General and administrative expenses increased to $41.6 million in Q3 2025 from $37.8 million in Q3 2024, mainly due to the inclusion of Exscientia's operations.
• REC-617 (CDK7 inhibitor) Phase 1/2 ELUCIDATE trial established the maximum tolerated dose (MTD) at 10 mg once-daily, demonstrating a manageable safety profile and preliminary anti-tumor activity, with a Phase 1 combination arm initiated.
• REC-7735 (PI3K H1047R inhibitor) was nominated as a Development Candidate, with IND-enabling studies now underway.
• Additional data for REC-4881 (MEK1/2 inhibitor) in FAP from the Phase 2 TUPELO study is expected in December 2025.

Sentiment

Score: 6

Explanation: While financial results show increased losses and decreased revenue, the company achieved significant partnership milestones, strengthened its cash position, and announced a strategic leadership transition with a highly qualified new CEO, indicating strong operational progress and future potential despite current financial headwinds.

Positives

• Achieved a $30 million milestone payment from Roche and Genentech for a second neuro map, bringing total upfront and milestone payments from partners to over $500 million.
• Maintained a strong cash position of approximately $785 million (unaudited) as of October 9, 2025, providing a cash runway through the end of 2027 without additional financing.
• Progressed the internal pipeline with REC-617 establishing a maximum tolerated dose (MTD) at 10 mg once-daily, demonstrating a manageable safety profile and early anti-tumor activity, and initiating a Phase 1 combination arm.
• Nominated REC-7735 as a Development Candidate, with IND-enabling studies underway, showcasing platform productivity.
• Appointed Dr. Najat Khan, an accomplished biopharma leader with extensive experience in data science, AI, and R&D from Johnson & Johnson and The Boston Consulting Group, as the new CEO and President.
• The leadership transition is designed for continuity and collaboration, with co-founder Chris Gibson transitioning to Chair of the Board and an Executive Advisor role.

Negatives

• Total revenue significantly decreased to $5.2 million for the third quarter of 2025, compared to $26.1 million for the third quarter of 2024.
• Net loss widened to $162.3 million for the third quarter of 2025, compared to a net loss of $95.8 million for the third quarter of 2024.
• Research and development expenses substantially increased to $121.1 million for the third quarter of 2025, from $74.6 million for the third quarter of 2024.
• General and administrative expenses increased to $41.6 million for the third quarter of 2025, compared to $37.8 million for the third quarter of 2024.
• Net cash used in operating activities increased to $325.7 million for the nine months ended September 30, 2025, compared to $243.7 million for the nine months ended September 30, 2024.

Risks

• Challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors.
• Ability to leverage and enhance the drug discovery platform.
• Ability to obtain financing for development activities and other corporate purposes.
• Success of collaboration activities.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Ability to obtain, maintain, and enforce intellectual property protections.
• Cyberattacks or other disruptions to technology systems.
• Ability to attract, motivate, and retain key employees and manage growth.
• Inflation and other macroeconomic issues.

Future Outlook

The company expects to continue advancing its internal pipeline and strategic partnerships, leveraging its Recursion OS platform to drive drug discovery and development. It anticipates over $100 million in partnership milestones by the end of 2026 and has a strong cash runway through the end of 2027 without requiring additional financing. Key pipeline milestones include additional data for REC-4881 in December 2025, early Phase 1 data for REC-1245 in 1H 2026, and potential Phase 1 initiations for REC-102 and REC-7735 in 2H 2026, with further data for REC-3565 expected in 1H 2027.

Management Comments

• "Recursion continues to deliver on our internal pipeline, our strategic partnerships and the continued building and refinement of the Recursion OS. On the partnership front, we are proud to announce that with the option of our second neuro map in the Roche and Genentech collaboration, we’ve achieved over $500 million in upfront and milestone payments from our partners to date as we continue to deliver novel insights and advance programs for some of the toughest disease areas. This is only the beginning of the returns we expect to see on the investment in our platform. With a strong cash runway through the end of 2027, we look forward to delivering on our pipeline and proving that building an end-to-end AI-enabled platform—combining massive proprietary datasets with industry-leading supercomputing capabilities and sophisticated AI models—is the critical infrastructure we need to realize real change in our industry." Chris Gibson, Co-Founder and CEO.
• "Our progress this quarter underscores the power of translating the Recursion OS into meaningful pipeline momentum. We continued to advance our clinical programs, with REC-4881 in the TUPELO study moving toward additional data later this year. We also progressed REC-617 into its first combination study and nominated REC-7735 as a new development candidate. On the partnered side, the delivery of our first-in-kind microglia map with Roche and Genentech highlights how phenomics can open new frontiers in neuroscience and other complex disease areas. These are the kinds of bold but pragmatic steps — in our own programs and through collaborations — that will be essential as we work to turn our platform insights into transformative medicines for patients." Najat Khan, Chief R&D and Chief Commercial Officer.
• "The Board’s unanimous decision to appoint Najat Khan as Recursion’s next CEO is a clear reflection of our confidence in her strategic acumen and proven track record of converting new science into tangible value. This transition has been planned to ensure absolute continuity of Recursion’s mission and vision. Chris’s guidance as our new Chairman guarantees we retain his unparalleled expertise in the TechBio space. We thank Chris for his exceptional leadership for the past twelve years, during which he transformed Recursion from an ambitious idea to the pioneer of a new sector, and we are united behind and excited for Najat to lead this next, critical chapter of execution and value creation for the company." Dr. Rob Hershberg, current Chairman.
• "After partnering with Najat Khan for the past 18 months, I have absolute faith that she is the right leader for Recursion’s next phase. Her unique and exceptional combination of strategic insight, scientific rigor, bold vision and commitment to leveraging technology to shift the way we discover treatments for patients through our platform is what’s needed for the company’s evolution. I am deeply honored to have built Recursion into the leading public TechBio company today and I look forward to continuing my unwavering dedication to our team and mission as Board Chairman." Dr. Chris Gibson, Co-founder and CEO.
• "I’m deeply honored to step into the role of CEO and President and build on the remarkable foundation established by Chris Gibson and the visionary founders of Recursion. Powered by exceptional people and united by a bold mission to decode biology to radically improve patients’ lives, Recursion has built something differentiated — a platform that unites biology, chemistry, and AI at unprecedented scale, a pipeline with meaningful near-term readouts, and a culture defined by curiosity, courage, and conviction. Throughout my career, I’ve always worked at the intersection of science, data, and business — building R&D portfolios, scaling AI organizations, and translating bold ideas into therapies that matter. Recursion brings all of that together: a company with immense potential at the forefront of technology and medicine. This is a pivotal chapter — one that will require bold and strategic focus, thoughtful navigation of complexity, and relentless determination to fully realize our vision. I’m excited to lead our next phase — turning platform insights into clinical proof, scaling where we have a true edge, and ultimately delivering transformational medicines for patients. I’m deeply grateful to Chris for his courageous vision and partnership, and I look forward to continuing to work with him and the Board as we build Recursion’s future together." Dr. Najat Khan.

Industry Context

Recursion Pharmaceuticals continues to solidify its position as a 'TechBio' leader, integrating AI, machine learning, and supercomputing into drug discovery. The appointment of Dr. Najat Khan, an expert in data science and AI from Johnson & Johnson, as CEO underscores the industry's increasing reliance on technological innovation to overcome traditional R&D challenges. The successful achievement of significant milestones with major pharmaceutical partners like Roche and Genentech validates the potential of AI-driven platforms in accelerating the identification of novel targets and therapeutic candidates in complex areas like neuroscience and oncology, aligning with a broader industry trend to enhance R&D efficiency and productivity.

Comparison to Industry Standards

• REC-617's GI-related toxicities (diarrhea 69%, nausea 41%, vomiting 28%) are noted as consistent with 'best-in-class potential' when compared to samuraciclib treatment (diarrhea 82%, nausea 77%, vomiting 80%) as reported by Coombes et al, 2023.
• REC-7735 demonstrated significant tumor regressions at low doses in preclinical studies, outperforming approved agents, while maintaining high selectivity (>100-fold) over wild-type PI3K.
• REC-4881 showed a 43% median reduction in total polyp burden in FAP patients, outperforming celecoxib in preclinical models.
• The company highlights its platform's ability to bring medicines to clinic faster and at lower cost compared to industry averages, citing metrics such as 'Time to candidate ID (months)' and 'Cost to IND ($M)' from Paul, et al., Nature Reviews Drug Discovery (2010).
• Achieving over $500 million in upfront and milestone payments places Recursion 'among a small group of pre-commercial biotechnology companies to achieve such scale,' indicating strong partnership validation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through a strengthened leadership team and continued pipeline/partnership progress, but short-term financial results show increased losses. The ATM facility utilization impacts share count.
• Employees: Leadership transition provides clarity on future direction. Dr. Gibson's advisory role ensures a smooth transition. Severance payments of $7.7 million were made in association with restructuring activities announced in June 2025.
• Customers/Patients: Continued advancement of drug candidates (e.g., REC-617, REC-4881) offers hope for new treatments in oncology and rare diseases.
• Partners (Roche, Genentech, Sanofi, Bayer, Merck KGaA): Continued successful collaboration and milestone achievements reinforce the value of Recursion's platform.

Next Steps

• Additional safety and efficacy data from the Phase 2 TUPELO study for REC-4881 in FAP expected in December 2025.
• Early Phase 1 safety and PK monotherapy data for REC-1245 expected in 1H 2026.
• Potential Phase 1 initiation for REC-102 expected in 2H 2026 (pending GLP toxicology data).
• Potential Phase 1 initiation for REC-7735 expected in 2H 2026 (pending GLP toxicology data).
• Early Phase 1 safety and PK monotherapy data for REC-3565 expected in 1H 2027.
• Preliminary ovarian combination data for REC-617 expected in 2027.
• Potential for multiple new project initiations and programs optioned by partners in 2026.
• The Company intends to file the Khan Letter and Gibson Advisory Agreement as exhibits to the periodic report covering the period during which the agreements were executed.

Key Dates

Recommendation

While the Q3 2025 financial results show a significant increase in net loss and a decrease in revenue, which are negative indicators, the company has achieved substantial operational milestones. The $30 million milestone from Roche and Genentech, bringing total partnership payments to over $500 million, validates the company's TechBio platform and partnership strategy. The strong cash runway through the end of 2027 provides financial stability for continued R&D. The strategic leadership transition, appointing a highly experienced AI/data science expert as CEO while retaining the co-founder as Chairman, suggests a well-planned evolution for future growth. Investors should hold to observe the execution of the new leadership and the progression of the pipeline and partnerships, as the long-term potential of the AI-driven drug discovery platform remains significant despite short-term financial challenges.

Keywords

Recursion Pharmaceuticals, RXRX, TechBio, AI drug discovery, biotechnology, pharmaceuticals, Q3 2025 earnings, CEO transition, Najat Khan, Chris Gibson, Roche collaboration, Genentech collaboration, pipeline update, clinical trials, oncology, rare disease, neuroscience, CDK7 inhibitor, PI3K H1047R inhibitor, MEK1/2 inhibitor, RBM39 degrader, MALT1 inhibitor, ENPP1 inhibitor, cash runway, milestone payments, corporate governance